SCHEMBL1799371

SCHEMBL1799371

COC(=O)c1cc(Cl)ccc1NC(=O)COCC(=O)Nc1cc(C(F)(F)F)cc(C(F)(F)F)c1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ RHOC P08134 4/20 0.53
▸ RHOA P61586 4/20 0.53
▸ TMPRSS4 Q9NRS4 5/20 0.50
▸ MEN1 O00255 4/20 0.50
▸ KMT2A Q03164 4/20 0.50
▸ P2RX1 P51575 4/20 0.50
▸ P2RX4 Q99571 3/20 0.50
▸ P2RX7 Q99572 3/20 0.50
▸ MAPT P10636 2/20 0.50
▸ IKBKB O14920 1/20 0.50
▸ CHUK O15111 1/20 0.50
▸ KDR P35968 1/20 0.50
▸ FLT3 P36888 1/20 0.50
▸ MYLK Q15746 1/20 0.50
▸ MAP4K5 Q9Y4K4 1/20 0.50
▸ GAA P10253 1/20 0.50
▸ XBP1 P17861 1/20 0.50
▸ NPSR1 Q6W5P4 1/20 0.50
▸ HTT P42858 1/20 0.49
▸ SMN1; SMN2 Q16637 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1799415 0.89 MPO (0.55) RHOCRHOATMPRSS4MEN1KMT2A
SCHEMBL1797516 0.85 ALDH1A1 (0.50) MEN1KMT2AMAPTGAASMN1; SMN2
SCHEMBL1015370 0.81 KDM4E (0.60) MEN1KMT2AMAPTGAASMN1; SMN2
SCHEMBL1796795 0.81 LMNA (0.45) MEN1KMT2AMAPTGAAHTT
SCHEMBL1015454 0.80 ALDH1A1 (0.51) MEN1KMT2AP2RX1MAPTGAA
SCHEMBL7125633 0.80 ALDH1A1 (0.62) MEN1KMT2AMAPTGAASMN1; SMN2
SCHEMBL418801 0.79 SERPINE1 (0.52) RHOCRHOATMPRSS4MEN1KMT2A
SCHEMBL9674267 0.78 ALDH1A1 (0.65) MEN1KMT2AMAPTGAAHTT
SCHEMBL1018800 0.78 GRIK1 (0.47) MEN1KMT2AMAPTGAANPSR1
SCHEMBL1015672 0.78 ALDH1A1 (0.58) MEN1KMT2AMAPTGAAKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7951806-B2 Plasminogen activator inhibitor-1 inhibitor RENASCIENCE CO., LTD. (JP) 2011-05-31 — — US disclosed
US-20090124620-A1 PLASMINOGEN ACTIVATOR INHIBITOR-1 INHIBITOR RENASCIENCE CO., LTD. (JP) 2009-05-14 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090124620-A1 PLASMINOGEN ACTIVATOR INHIBITOR-1 INHIBITOR SERPINE1, SERPINC1, SERPINB1 RHOC 3393/4885RHOA 751/4885TMPRSS4 383/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback